Acrux Limited (ASX:ACR) Launches Dapsone 7.5% Gel in the United States
Product Launch
Acrux Limited and its commercial partner TruPharma have launched Dapsone 7.5% Gel in the United States. The prescription medicine is used topically to treat acne vulgaris in children aged nine years or older.
Market Differentiation
The product is marketed in a tube presentation, distinguishing it from competitors’ pump bottle packaging. Manufactured and packaged in the United States, the gel is available in 60 gram and 90 gram presentations, aligning with market standards.
Market Potential
According to IQVIA, annual sales for competing products exceeded USD$43 million and 171,000 packs in the US for the year ending December 2024.
Executive Comments
Acrux CEO and Managing Director Michael Kotsanis stated, “We are very excited to launch this differentiated product which has been developed in house by the Acrux R&D team. Our scientists believe that our tube presentation is more convenient and easier to use than the alternative marketed products that are available in a bottle pump pack. It contains less plastic, leading to less waste and is less intensive to manufacture than a bottle pump pack. Tube presentations are far more widely used across broad consumer, over the counter and prescription categories of products, compared to bottle pump packaging. This launch is in addition to the Dapsone 5%, Gel product launched in 2024. The launch further demonstrates the capability of the Acrux team to execute the Company’s strategy to develop and commercialise our pipeline of topically applied prescription pharmaceutical products.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
